From: Protein profiling of ovarian cancers by immunohistochemistry to identify potential target pathways
Biomarker | Serous mean (sd) | Clear cell mean (sd) | Endometrioid mean (sd) | Other mean (sd) |
---|---|---|---|---|
1 Androgen receptor | .27(.44) | .10(.31) | .27(.45) | .12(.33) |
2 BCRP* | .85(.36) | .85(.37) | .65(.49) | .72(.46) |
3 c-kit | .05(.22) | .00(.00) | .00(.00) | .00(.00) |
4 ER* | .47(.50) | .14(.36) | .50(.51) | .39(.50) |
5 ERCC1 | .24(.43) | .33(.48) | .04(.19) | .25(.44) |
6 Her2/Neu | .01(.09) | .00(.00) | .00(.00) | .00(.00) |
7 MGMT*** | .93(.25) | .62(.50) | .93(.26) | .89(.32) |
8 MRP1 | .89(.32) | .85(.37) | .92(.27) | .92(.27) |
9 PDGFR | .18(.38) | .15(.37) | .23(.43) | .16(.37) |
10 PGP | .19(.39) | .24(.47) | .21(.42) | .14(.36) |
11 PR | .39(.49) | .19(.40) | .50(.51) | .36(.49) |
12 PTEN | .65(.48) | .48(.51) | .43(.50) | .61(.50) |
13 RRM1** | .47(.50) | .14(.36) | .24(.44) | .57(.50) |
14 SPARC MONO | .11(.32) | .24(.47) | .10(.30) | .16(.37) |
15 SPARC POLY | .04(.20) | .00(.00) | .00(.00) | .00(.00) |
16 TOP2A | .39(.49) | .20(.41) | .23(.43) | .40(.50) |
17 TOPO1 | .89(.32) | .86(.36) | .89(.32) | .93(.26) |
18 TS | .15(.35) | .05(.22) | .08(.27) | .16(.37) |